Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Shares of COVID-19 vaccine maker Moderna (MRNA) rose 13.1% on Jan 2, after analysts at Oppenheimer recently upgraded the stock’s recommendation to Outperform, with a price target of $142 per share.Per the Oppenheimer analysts, Moderna could become ‘a five-product commercial company by 2026’. These analysts were encouraged by Moderna’s upcoming product launches over the next 12 to 18 months, which are expected to boost sales in 2025 and positive pipeline expectations.Over the next two years, Oppenheimer anal ...